Literature DB >> 22635088

Unfavorable effects of hyperprolactinemia in autoimmune endocrine disorders.

Robert Krysiak1, Agnieszka Kędzia, Bogusław Okopień.   

Abstract

Prolactin is a hormone with a multidirectional proinflammatory action. It has an anti-apoptotic effect, enhances proliferative response to antigens and mitogens, as well as enhances the production of immunoglobulins and autoantibodies. Increased prolactin levels are commonly observed in various organ and multi-organ specific autoimmune diseases. In our article, we report a case of a woman who developed progression of autoimmune thyroid disorder and developed insufficiency of the zona glomerulosa when her prolactin levels were increased. A normalization of plasma prolactin levels by quinagolide and replacement of risperidone with aripiprazole improved her clinical condition. Our study suggests that, in some patients, hyperprolactinemia may predispose to the development and progression of autoimmune disorders of endocrine glands.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22635088

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  3 in total

Review 1.  Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials.

Authors:  Meiling Meng; Wei Li; Shaowei Zhang; Hongyan Wang; Jianhua Sheng; Jijun Wang; Chunbo Li
Journal:  Shanghai Arch Psychiatry       Date:  2015-02-25

2.  Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents.

Authors:  Lucia Margari; Emilia Matera; Maria G Petruzzelli; Marta Simone; Anna L Lamanna; Adriana Pastore; Vincenzo O Palmieri; Francesco Margari
Journal:  Int Clin Psychopharmacol       Date:  2015-03       Impact factor: 1.659

3.  Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia.

Authors:  Qijing Bo; Fang Dong; Xianbin Li; Zhimin Wang; Xin Ma; Chuanyue Wang
Journal:  BMC Psychiatry       Date:  2016-11-09       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.